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The Natural Cytotoxicity Receptors (NCRs), NKp46, NKp44, and NKp30, were
some of the first human activating Natural Killer (NK) cell receptors involved in the
non-MHC-restricted recognition of tumor cells to be cloned over 20 years ago. Since
this time many host- and pathogen-encoded ligands have been proposed to bind the
NCRs and regulate the cytotoxic and cytokine-secreting functions of tissue NK cells.
This diverse set of NCR ligands can manifest on the surface of tumor or virus-infected
cells or can be secreted extracellularly, suggesting a remarkable NCR polyfunctionality
that regulates the activity of NK cells in different tissue compartments during steady
state or inflammation. Moreover, the NCRs can also be expressed by other innate and
adaptive immune cell subsets under certain tissue conditions potentially conferring NK
recognition programs to these cells. Here we review NCR biology in health and disease
with particular reference to how this important class of receptors regulates the functions
of tissue NK cells as well as confer NK cell recognition patterns to other innate and
adaptive lymphocyte subsets. Finally, we highlight how NCR biology is being harnessed
for novel therapeutic interventions particularly for enhanced tumor surveillance.
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INTRODUCTION
Natural Killer (NK) cells constitute a population of large, granular lymphocytes that are located
in the blood, lymphoid organs, such as the thymus and spleen, and non-lymphoid organs, such as
the liver and uterus, as well as tissues, such as skin (1–4). NK cells were originally identified based
on their ability to lyse certain tumor and virally infected cells (5, 6). In contrast, normal healthy
cells that express sufficient levels of MHC class I molecules are spared from NK cell attack (7).
Subsequently, the process whereby the effector functions of developing NK cells are adapted to
the levels of MHC class I expressed by a host, termed NK cell “education”, was described (8, 9). It
was during this exciting era of discovery that the functional activity of NK cells was shown to be
exquisitely controlled by inhibitory receptors specific for MHC class I molecules, such as the Ly49
receptors in mice (10), and the Killer immunoglobulin-like receptors (KIR) in humans (11–14).
Fully educated NK cells efficiently lyse target cells lacking MHC class I molecules, implying the
existence of a set of activating NK cell receptors for non-MHC class I ligands expressed on target
cells that are either not present or expressed at much lower levels on healthy cells, although formal
molecular evidence for this was lacking during this period.
In contrast to T and B lymphocytes, NK cells lack the expression of rearranging cell-surface
antigen receptors and so it remained unclear how NK cells might be aroused by surface ligands
expressed by tumor or virus-infected cells. Even though NK cells lack expression of the T cell
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receptor (TCR), they still retain expression of the ζ chain
from the CD3 signaling complex. These data suggested that
NK cells express cell-surface receptors that might share similar
downstream signaling mechanisms to the TCR but are regulated
by different ligands. For example, whereas T cells recognize
short antigenic peptides in the context of MHC class I, NK
cells can be inhibited by the expression of MHC class I
molecules. Thus, NK cells express activating receptors that
may recognize ligands expressed by tumor and virus-infected
cells in a non-MHC-restricted fashion. Whilst the function and
downstream signaling events of the low affinity Fc receptor,
CD16, that mediates antibody-dependent cellular cytotoxicity
(ADCC) were well-defined at this time (15–17), the identity of
other activating receptors and their cognate ligands involved
in the natural cytotoxicity of NK-susceptible targets cells were
largely unknown, which stimulated further research into the
receptors that trigger NK cell cytotoxicity.
The Natural cytotoxicity receptors (NCRs) were originally
identified by the Moretta group almost 20 years ago in a
series of elegant redirected lysis experiments using human NK
cells (18–20). The NCR family are comprised of three type I
transmembrane (TM) receptors, termed NKp46, NKp44, and
NKp30, which are encoded by the genes, NCR1, NCR2, and
NCR3, respectively. Even though the NCRs were discovered
based on their ability to induce NK cell cytotoxicity of
monoclonal antibody (mAb)-coated tumor cell targets, the
blocking of individual NCR activity using soluble mAbs had only
a mild effect on NK cell cytotoxicity and different tumor cells
varied in their susceptibility. Combinations of soluble mAbs to
the NCRs were found to have a much stronger blocking effect for
selected tumor cell-lines indicating that the NCRs can cooperate
with each other to mediate NK cell cytotoxicity of certain tumor
cell-types (18, 20, 21). These results suggest that the coordinated
expression of NCR ligands by different tumor cell-types as well as
the level of NCR expression by different NK cell clones governs
NK cell cytotoxicity, which is counterbalanced by the level of
MHC class I expressed for a given tumor cell type.
Recent success in identifying the various ligands for
the NCRs is now beginning to illuminate the biological
roles that this important class of receptors plays in NK
cell surveillance of malignant or pathogen-infected cells
and in different tissue microenvironments. One striking
aspect that has become apparent is that each NCR may
interact with several different pathogen- and host-encoded
molecules that can either be expressed on cell-surfaces,
secreted or shed extracellularly, or incorporated into the
extracellular matrix (ECM). Moreover, cytokines expressed
in the local tissue microenvironment can influence which
particular NCR isoform is expressed. These different NCR
isoforms have now been shown to deliver either activating or
inhibitory signaling functions depending on their interaction
with ligand. Here we review NCR biology in the different
tissue NK cell populations as well as other innate and
adaptive immune subsets, their functional interactions with
a diverse set of cellular- and pathogen-encoded ligands,
and the potential for these interactions to be harnessed for
tumor immunotherapy.
FIGURE 1 | Overview of individual NCR domain structures. The domain
architecture of the NCRs and TM signaling adaptors encoding ITAM residues
(green boxes) are displayed. The NCRs are type I TM proteins expressed on
the plasma membrane of immune cells. NKp46 (yellow) has two Ig-like
domains, whereas NKp30 (pink) and NKp44 (blue) possess only one Ig-like
domain. All NCRs contain either a positively charge arginine (R) or lysine (K)
residue in their hydrophobic TM domains that can form a salt bridge with a
corresponding aspartate (D) residue in the TM domains of the ITAM adaptors;
CD3, FcR, or DAP12, respectively. The cytoplasmic domains of the NCRs do
not encode any inherent signaling capacity with the exception of NKp44 that
contains a putative ITIM sequence (red) in its cytoplasmic tail and thus
maintains potential for inhibitory signaling.
NKp46
Molecular cloning of the cDNA for NKp46 (also known as
natural cytotoxicity receptor 1, NCR1) revealed an open reading
frame (ORF) encoding a 46 kDa type I TM protein belonging
to the immunoglobulin (Ig) superfamily characterized by two
extracellular C2-type Ig-like domains followed by a stalk region
(Figure 1) (21). The two Ig-like domains of NKp46 are arranged
in a V-shaped conformation positioned at an angle of 85◦ to
each other similarly to the D1D2 domains of KIRs and Leukocyte
Ig-like receptors [LILR, also known as ILTs (22)] that share a
distant ancestral evolutionary relationship with NKp46 (23, 24).
The cytoplasmic domain of NKp46 lacks an Immunoreceptor
Tyrosine-based Activation Motif (ITAM), instead the TM
domain contains a positively charged arginine residue that
mediates association with the negatively charged aspartate
residue in the TM domain of the ITAM signaling adaptors,
CD3ζ or the Fc receptor common γ (FcRγ) (Figure 1). The gene
encoding NKp46, NCR1, is located in the Leukocyte Receptor
Complex (LRC) on chromosome 19q13.4 (25). A murine NCR1
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ortholog has also been cloned and maps to mouse chromosome
7, the syntenic region of human chromosome 19 (21).
The expression of NKp46 on NK cells is conserved across
all mammalian species (26). In humans, NKp46 is expressed
by all CD56dimCD16+ and CD56brightCD16− human NK cells
irrespective of their activation status (19). Cross-linking with
anti-NKp46 mAb results in calcium release and the secretion of
IFN-γ and TNF-α by NK cells and blocking NKp46 signaling
with specific mAbs can result in reduced NK cell cytotoxicity
of certain tumor cell-lines, although the most potent blocking
activity is observed in combination with mAbs to other NCRs
(19, 21). Subsequent studies have now shown that NKp46 is also
expressed by innate lymphoid cells (ILCs) of group 1 (ILC1)
and a subset of group 3 ILCs (NCR+ ILC3) (27, 28), γδ T cells
(29, 30), a population of oligoclonally expanded intraepithelial
(IEL) cytotoxic T lymphocytes (CTL) (31) and a population of
IL-15-dependent innate-like IEL lacking surface TCR expression
(32) in celiac disease patients, and umbilical cord blood (UCB) T
cells cultured in IL-15 (33). NKp46 is also expressed bymalignant
NK, NKT, and T cell lymphomas (32, 34–36) (Table 1).
NKp44
The functional activity of NK cells against tumor cells deficient
in the expression of MHC class I molecules is greatly enhanced
by culture in IL-2, suggesting that NK cells upregulate activating
receptors for additional non-MHC ligands. Whereas, NKp30 and
NKp46 are constitutively expressed by resting NK cells obtained
from peripheral blood, the expression of NKp44, also known
as natural cytotoxicity receptor 2 (NCR2), is upregulated on
NK cells stimulated by IL-2, IL-15 or IL-1β, particularly on
the CD56bright subset (20, 37–39). NKp44 is a 44 kDa protein
comprised of a single extracellular V-type Ig (IgV) domain
followed by a long stalk region and a hydrophobic TM domain
containing a charged lysine residue that mediates association
with the ITAM adaptor, DAP12 (also known as KARAP and
TYROBP) (Figure 1) (40, 41). Structural studies have shown that
the IgV domain of NKp44 forms a saddle-shaped dimer with a
positively charged groove on one side of the protein (42).
The gene for NKp44 (NCR2) is encoded in the human TREM
receptor locus at 6p21.1, which is centromeric of the MHC (20,
43) and is also found in several primates species but not in mice
(44). Three major transcripts are expressed from NCR2 (NKp44-
1,−2, and−3) that have been investigated in detail. Whereas,
NKp44-2 and NKp44-3 are predicted to encode proteins
with short cytoplasmic domains with no inherent signaling
capacity, NKp44-1 is predicted to encode a protein with a long
cytoplasmic tail containing the amino acid sequence “ILYHTV”
that conforms to the sequence of an Immunoreceptor Tyrosine-
based Inhibition Motif (ITIM). The NKp44-1 isoform thus has
the potential for inhibitory as well as activating signaling since
this isoform also retains the capacity to associated with DAP12.
A molecular characterization of the NKp44-1 ITIM showed that
it has the potential to be phosphorylated in the NK92NK cell-line
but could not recruit the phosphotyrosine phosphatases, SHP-
1 or SHP-2, or the 5
′
-inositol phosphatase, SHIP, in order to
mediate cellular inhibition (45). Thus, it was concluded that the
activating function of NKp44-1 is not influenced by the presence
of the cytoplasmic ITIM.Nevertheless, NKp44-1 has the potential
for dual signaling functions through the cytoplasmic ITIM and
association with the ITAM adaptor, DAP12.
Like the other NCRs, NKp44 has also been shown to be
expressed by ILC1 (46, 47), ILC3 (48, 49), γδ T cells (30,
50), oligoclonally expanded IEL CTL in celiac disease patients
(31), and UCB T cells cultured in IL-15 (33), in addition to
plasmacytoid dendritic cells where NKp44may be involved in the
regulation of type I interferon secretion (51) (Table 1).
NKp30
NKp30, also known as natural cytotoxicity receptor 3 (NCR3),
was identified as a 30 kDa protein that, similarly to NKp46,
is expressed on all mature resting and activated NK cells (18).
Molecular cloning of the NKp30 cDNA revealed an open reading
frame predicted to encode one extracellular IgV domain and a
hydrophobic TM domain with a charged arginine residue capable
of associating with the ITAM adaptors, CD3ζ and/or FcRγ
(Figure 1) (18, 88). The crystal structure of NKp30 reveals some
structural similarity to CTLA-4 and PD-1 and NKp30 is thus
considered a member of the CD28 family of receptors (83, 89).
Both NKp30 and NKp46 have reduced surface expression on
adaptive memory NK cells most likely due to the downregulated
expression of the FcRγ signaling chain required for the surface
expression of these receptors (90, 91).
In humans, NCR3 is encoded in the class III region of the
Major Histocompatibility Complex (MHC) but was found to be
a pseudogene in 13 strains of mice with the exception of Mus
caroli (92). Six alternatively spliced transcripts are transcribed
from the NKp30 gene, termed NKp30a-f. Three NKp30 isoforms,
NKp30a, NKp30b, and NKp30c, which differ in their cytoplasmic
tails due to alternative splicing in exon 4, have been studied in
detail. Whilst NKp30a and NKp30b evoke NK cell activation,
the NKp30c isoform was shown to elicit secretion of the
immunosuppressive cytokine, IL-10, from NK cells (93). NKp30
has also been shown to be expressed by γδ T cells (30), CD8+ T
cells (94), and UCB T cells cultured in IL-15 (33).
NCRs AND THEIR LIGANDS IN CANCER
The NCRs were first characterized based on their ability to evoke
the cytotoxic and cytokine-secreting functions of NK cells toward
tumor cell-lines in vitro. Several studies have now provided
evidence that the NCRs are involved in tumor surveillance in
vivo. For example, genetic deficiency of NKp46 in mice results
in the impaired clearance of subcutaneous T lymphoma (95)
and melanoma (96) tumors and melanoma lung metastases
(97, 98). Moreover, transgenic overexpression of NKp46 resulted
in the enhanced clearance of melanoma lung metastases (99).
Intriguingly, enhanced NKp46 signaling elicited IFN-γ secretion
and increased tumor deposition of fibronectin, which altered the
solid tumor architecture and resulted in the decreased formation
of melanoma metastases (100). Importantly, the T lymphoma
and melanoma cell-lines used in these studies all expressed cell-
surface ligands for NKp46. Moreover, in human patients with
melanoma, normal melanocytes had negligible expression of
NKp46 ligands in comparison to malignant melanocytes deep
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TABLE 1 | Expression of Natural cytotoxicity receptors and their ligands.
Receptor Gene Cellular expression Ligands Ligand-induced
signal
References
NKp46 NCR1 NK cells, ILC1, NCR+ ILC3,
Small intestine TCRαβ+ CD8+ IEL,
Small intestine TCRαβ− innate-like IEL,
TCRγδlowCD3−,
Expanded peripheral blood γδ T cells
(Vδ1+),
NK, NKT and T lymphomas,
Cord blood T cells cultured in IL-15
Heparan sulfate (HS) gylcosaminogylcans (GAGs)
HA (hemagglutinin) of influenza virus
HA of human vaccinia virus
HN of avian Newcastle disease virus, Sendai virus
and human parainfluenza virus
(DBL)-1 α domain of Plasmodium falciparum
erythrocyte membrane protein (PfEMP1)
Vimentin expressed on cells infected with
Mycobacterium tuberculosis
Unidentified ligand expressed by Fusobacterium
nucleatum
Unidentified ligand expressed by pancreatic β-cells
C. glabrata Epa proteins





















NKp44 NCR2 NK cells, ILC1, ILC3,
Plasmacytoid dendritic cells,
Small intestine TCRαβ+ CD8+ IEL,
Expanded peripheral blood γδ T cells
(Vδ1+),
Cord blood T cells cultured in IL-15
HS GAGs
Syndecan-4 (in cis)
HA of Influenza virus
HN of avian Newcastle disease virus, Sendai virus




NKp44L expressed on tumor cells, bystander CD4+
T cell during HIV infection, or cartilage-derived
chondrocytes
Domain III envelope protein from West Nile and
Dengue viruses
Unknown ligand(s) on Mycobacterium tuberculosis,






















NKp30 NCR3 NK cells,
CD8+ T cells,
Expanded peripheral blood γδ T cells
(Vδ1+),
ILC2
Cord blood T cells cultured in IL-15
HS GAGs
HA of human vaccinia virus
pp65, main tegument protein of human
cytomegalovirus
(DBL)-1 α domain of






















within melanoma lesions that stained strongly for NKp46-Fc
showing that NKp46 ligands can be upregulated on malignantly
transformed cells but are not expressed by healthy cells (101).
Several cellular ligands for the NCRs have now been proposed
(Table 1) and we discuss these here in the context of anti-tumor
responses (Figure 2).
Heparan Sulfate Glycosaminoglycans
Heparan sulfate (HS) glycosaminoglycans (GAGs) are found on
cell surfaces and within the ECM and consist of long, branched,
anionic polysaccharides that are incorporated into proteins to
form HS proteoglycans (HSPGs), such as the syndecans and
glypicans, that form an integral and dynamic component of
normal tissue architecture (102, 103). HSPGs also play vital roles
in tumor progression allowing cancer cells to proliferate, elude
immunosurveillance, invade neighboring tissues, andmetastasize
to distal tissue sites from the primary tumor. The negative charge
of HSPGs can also provide docking sites for the basic domains of
various secreted factors, such as chemokines and growth factors
like fibroblast growth factor (104).
All three NCRs have been reported to bind to different
HS sequences. HS GAGs are heterogenous in structure with
a preference for highly sulfated HS structures and with each
NCR possessing a distinct HS binding specificity. NKp30 and
NKp46 binding to HS is similar although the binding varies
significantly. In contrast, NKp44 displays a very different binding
pattern toNKp30 andNKp46 (52, 77). A cis interaction of NKp44
with the cell-associated HSPG, syndecan-4, has been reported.
The interaction between syndecan-4 and NKp44 was shown to
regulate the membrane distribution of NKp44, and constitutively
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FIGURE 2 | Expression of the NCRs and their Ligands. Schematic representation of the expression of the NCRs on NK cells and the NCR ligands by tumors (green)
or pathogens or cells infected with pathogens (light blue). NKp30 and NKp46 are expressed by resting (pink) as well as activated (orange) NK cells, whereas NKp44 is
only expressed by NK cells activated with IL-2 or IL-15 (arrow). PCNA, BAT3 and NKp44L are nuclear proteins but the pathways whereby they become expressed on
the surface of tumor cells remain to be identified. NKp44L is a splice variant of the Mixed-lineage leukemia 5 (MLL5) protein encoding a C-terminal modification
reported to mediate cell-surface expression of NKp44L on tumor cells. Similarly, the pathway whereby vimentin becomes expressed on the surface of M. tuberculosis
infected cells also remains to be described.
dampen NKp44 activity. Treatment of NK cells with soluble HS
was proposed to disrupt the cis association with syndecan-4 and
potentiate NKp44 signaling (65).
It is an attractive hypothesis to speculate that NK cells could
utilize the NCRs to sense changes in HSPGs in the tumor
microenvironment or possibly even during infection to activate
NK cell cytotoxicity and IFN-γ secretion, particularly since
several cancers exhibit aberrant regulation of key HS biosynthetic
enzymes, such as 3-O- and 6-O-Sulfotransferases, and catabolic
enzymes, such as heparanase and the HS endosulfatases, SULF1
and SULF2 (105). Conversely, pathogens or tumor cells could
modify HSPGs to evade NK cell surveillance. Indeed, the over-
expression of telomere repeats binding factor 2 (TRF2), a key
factor in telomere protection, can result in the upregulation
of heparan sulfate-glucosamine 3-O-sulfotransferase 4 (HS3ST4)
in cancer cells by binding to the interstitial telomeric repeat
located within the HS3ST4 intron (106). Silencing of HS3ST4
expression using short hairpin RNAs in cancer cells resulted in
increased tumor infiltration of activated NK cells. Thus, aberrant
sulfation of cell-surface HSPGs canmodify the capacity for tumor
surveillance by NK cells. However, the precise role of the NCRs
and HS GAGs in NK cell tumor surveillance remains unclear
since NKp30-dependent NK cell cytotoxicity was unaffected by
GAG-deficiency or heparanase treatment of tumor cell targets
(78). It is possible that HS GAGs may also serve as “co-receptors”
facilitating interactions with other NCR ligands, such as growth
factors like PDGF-DD (67).
B7-H6
K562 cells are highly susceptible to lysis by human NK cells,
which is mediated by NKp30-mediated recognition of a tumor
cell-surface ligand. A proteomics approach designed to trap
ligands bound to an NKp30 Fc-fusion protein by chemical cross-
linking resulted in the co-immunoprecipitation of B7-H6 from
K562 cell lysates (84). B7-H6 is type I TM protein possessing
two extracellular Ig-like domains and is a member of the B7
family of costimulatory molecules. Like other members of the
B7 family, the extracellular domain of B7-H6 is composed of
a membrane distal IgV domain and a membrane proximal IgC
domain (83). NKp30 was found to use the front and back β-
sheets of its IgV domain to engage the side and face of the
corresponding β-sandwich of B7-H6, whereas CTLA-4 and PD-1
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use only the front β-sheet of their Ig-like domains to contact their
ligands. B7-H6 contacts NKp30 through the complementarity-
determining region (CDR)-like loops of its IgV domain, thus
resembling the binding interaction of antibodies with antigen,
which is not observed for CTLA-4 binding to B7.1/B7.2 or PD-1
binding to PD-L1/PD1-L2 (83).
B7-H6 expression was found to be negligible on normal
cells but was highly expressed by a wide range of tumor
cells, showing that cellular transformation serves as a mode
of immunosurveillance in the innate immune system (84). In
support of this, the expression of B7-H6 is upregulated by the
proto-oncogene Myc (107) and is associated with greater overall
survival of patients with oral squamous carcinoma (108). In
contrast, some tumors are thought to escape NKp30 recognition
by metalloprotease-mediated shedding of B7-H6 from the cell-
surface (109). The soluble form of B7-H6 is detected in the
serum of patients with hepatocellular carcinoma (110), metastatic
gastrointestinal tumors (GIST) (111), neuroblastoma (112, 113),
and peritoneal fluid from ovarian cancer patients (114), and
is associated with impaired NKp30 expression and NK cell
dysfunction as well as poor overall patient survival.
Differential expression of transcripts encoding the different
NKp30 isoforms have also been associated with cancer prognosis.
The preferential expression of the immunosuppressive NKp30c
isoform over the activating NKp30a and NKp30b isoforms was
associated with the reduced overall survival of GIST patients
treated with imatinib mesylate (93, 111). The NKp30c isoform
was reported to trigger secretion of the immunosuppressive
cytokine IL-10 from NK cells and was associated with NK cell
dysfunction characterized by defective NK cell degranulation
and secretion of IFN-γ and TNF-α. Interestingly, polymorphism
in the 3′ untranslated region of NCR3 can result in the
preferential expression of the immunosuppressive NKp30c
isoform by NK cells and predicted the clinical outcome for
GIST patients independently from KIT mutation (93). In
pediatric neuroblastoma, expression of the immunostimulatory
(NKp30a/b) versus immunosuppressive (NKp30c) isoforms is
also associated with a higher risk of relapse and elevated
serum levels of soluble B7-H6 that inhibit NK function were
associated with the bonemarrowmetastasis and chemoresistance
of neuroblastoma cells (112, 113). Expression of B7-H6 is also
detected on monocytes and neutrophils treated with TLR ligands
and pro-inflammatory cytokines. A soluble form of B7-H6 was
also detected under these conditions and in sepsis patients
suggesting B7-H6 may also regulate NK cell activity via NKp30
isoforms during inflammation (115).
Nuclear Proteins
NKp44 has been reported to bind to several intracellular ligands
that have been proposed to be aberrantly expressed on the
cell-surface of tumor or virus-infected cells. An NKp44 ligand
was reported to be expressed on the surface of tumor or
CD4+ T cell from HIV patients (71) that was dependent on
expression of HIV gp41. Moreover, a peptide sequence derived
from HIV gp41 was shown to upregulate the expression of
this NKp44 ligand on CD4+ T cells (71). A yeast two-hybrid
screen using a cDNA library from the Jurkat T cell-line was
employed to find interacting partners for NKp44 (72) and a
cDNA encoding a splice variant of the mixed-lineage leukemia
protein-5 (MLL5) was subsequently cloned. MLL5 is normally
a nuclear antigen but the cDNA sequence revealed a new exon
resulting in a transcript encoding an MLL5 variant protein with
an alternative C-terminal amino-acid sequence. This new protein
termed NKp44L was reported to be expressed on the cell-surface
and in the cytoplasm of various tumor cell-lines but not in
normal tissues (72). However, the mechanism driving NKp44L
cell-surface expression remains obscure. NKp44L expression has
also been reported on human articular chondrocytes (73).
NKp44 was also reported to interact with Proliferating cell
nuclear antigen (PCNA). PCNA is found in the nucleus and
functions as a co-factor for DNA polymerase δ that helps leading
strand synthesis during DNA replication (116). PCNA was
identified as anNKp44 ligand following a screen of a yeast surface
display library using an NKp44-Fc fusion protein (69). Cell-
surface expression of PCNA was reported following transfection
into HeLa cells, which reduced NK cell cytotoxicity and IFN-γ
secretion. PCNA was found to localize at the plasma membrane
where it was shown to form an immunological synapse with
NKp44 to mediate NK cell inhibition. The inhibition of NK cell
signaling was reported to occur via the NKp44-1 splice variant
that potentially encodes a cytoplasmic ITIM (69). The interaction
of PCNA with NKp44 was proposed to form a unique interaction
capable of transducing an inhibitory rather than an activating
signal (69, 117). PCNA has also been shown to associate with
Human Leukocyte Antigen (HLA) class I molecules on the
cell-surface of tumor cells to form an inhibitory ligand for
NKp44 and suppression of NK cell cytotoxicity (70). The authors
suggested that NCR ligands could act as Damage-Associated
Molecular Patterns (DAMPs) through association with HLA
class I molecules (118). Interestingly, preferential expression of
the transcript encoding the ITIM-bearing NKp44-1 isoform is
associated with poor survival in acute myeloid leukemia and was
proposed to be a novel target for checkpoint blockade on NK
cells (119).
HLA-B-associated transcript 3 (BAT3), also known as Bcl2-
associated anthogene 6 (BAG6), is another intracellular protein
that was identified as an NKp30 ligand using a yeast two-
hybrid screening approach (80). BAT3 is a multifunctional
molecular chaperone that contributes to several cell processes
including apoptosis, gene regulation, protein synthesis, protein
quality control and protein degradation. For example, BAT3
can function by preventing the aggregation of misfolded and
hydrophobic-patch containing proteins ensuring their correct
delivery to the endoplasmic reticulum or the sorting of
proteins that have mislocalized to the cytoplasm for proteosomal
degradation (120). BAT3 also accumulates in the nucleus where it
is involved in regulating apoptosis following DNA damage (121).
BAT3 was proposed to be released from tumor cells to engage
NKp30 and trigger NK cell activation (80, 81). Exosomal release
of BAT3 was also reported to promote NK:DC cross-talk (82).
In contrast, the release of a soluble form of BAT3 found in the
plasma of CLL patients was found to suppress NK cell activation
through competition for the exosomal form of BAT3 and other
tumor ligands (122, 123).
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Platelet-Derived Growth Factor-DD
Growth factors (GFs) are important for guiding various cellular
and developmental processes and GF pathways are often
dysregulated in cancer. The platelet-derived growth factor
(PDGF) family are comprised of four polypeptides that can
assemble into at least five dimeric isoforms, PDGF-AA, PDGF-
BB, PDGF-AB, PDGF-CC and PDGF-DD, and which engage
with the receptor tyrosine kinases, PDGF receptor (PDGFR)-
α and PDGFR-β (124). Cancer cells frequently express PDGFs
which can trigger autocrine and paracrine PDGFR signaling
to promote tumor growth, proliferation, stromal recruitment,
angiogenesis, epithelial to mesenchymal cell transition, and
metastasis (125).
PDGF-DD was identified as a ligand for NKp44 by
screening a library of secreted proteins with NKp44 GFP
reporter cells (67). PDGF-DD induced NK cell degranulation
and the secretion of IFN-γ and TNF-α from NK cells and
ILC1 as well as TNF-α secretion from ILC3 in agreement
with a previous study (67, 126). IFN-γ and TNF-α secreted
by NK cells stimulated with PDGF-DD could induce cell
cycle arrest in melanoma, ovarian, and breast tumor cell-
lines. Thus, innate immune cells have the capacity to sense
the expression of GFs by tumor or tumor-associated stroma
cells and potentially even infected or developing tissues to
evoke NK cell responses. Remarkably, the upregulation of
PDGF-DD-induced NK cell cytokines and chemokines and
the downregulation of tumor cell cycle genes correlated with
NCR2 expression and was associated with greater survival in a
cohort of glioblastoma patients. Moreover, transgenic expression
of NKp44 in mouse NK cells resulted in greater control of
tumors expressing PDGF-DD showing that whilst PDGF-DD
can support tumor growth it also exposes tumor cells to NK
cell immunosurveillance via NKp44. The ability of NK cells
and ILCs to engage in GF surveillance via NKp44 is a new
immunological paradigm that remains to be fully explored (67).
Interestingly, a polymorphism in PDGFD is associated with
serum IFN-γ levels in humans (127), suggesting the PDGF-
DD/NKp44 interaction may play wider biological roles beyond
cancer (Table 2).
Nidogen-1
The ECM protein, Nidogen-1 (NID1, also known as Entactin)
was identified as an NKp44 ligand, in another screen to
identify soluble ligands that might regulate NCR activity and
NK cell function (68). NID1 is an essential component of
the basement membrane (BM) where it plays a role in BM
assembly and stabilization, as well as adhesion between cells
and the ECM (128). Soluble NID1 can be detected in the
serum from patients with ovarian and lung cancer that may
be derived from proteolytic degradation by cathepsin-S (CatS)
(129, 130). Thus, it is conceivable that the release of NID1
into extracellular fluids may regulate the activity of activated
NK cells in the blood or at specific tissue sites. Indeed, CatS-
degradation and release of NID1 was proposed to reflect the
loss of BM integrity, which is frequently associated with invasive
tumors. Soluble NID1 was able to inhibit cytokine secretion
mediated by PDGF-DD or cross-linking with anti-NKp44 mAbs.
Consequently, the release of soluble NID1 was proposed to be a
novel immunosuppressive mechanism exploited by tumor cells
to evade NK cell surveillance (68).
Galectin-3
Galectin-3 is a β-galactoside-binding lectin that has been
reported to be a critical immune regulator in the tumor
microenvironment (131). Galectin-3 can be expressed in the
cytoplasm, nucleus, cell-surface, or extracellularly depending on
the cell type and proliferative status. For example, extracellular
galectin-3 can facilitate metastasis by promoting cell adhesion,
invasiveness and immune evasion.
The genetic manipulation of galectin-3 expression levels in
tumor cells showed that downregulation of galectin-3 lead to
tumor growth inhibition, whereas the upregulation of galectin-
3 led to enhanced tumor growth in human cervical and breast
cancer models. Moreover, soluble galectin-3 released from tumor
cells was found to bind specifically to NKp30 thereby inhibiting
NKp30-mediated cytotoxicity. Thus, it was proposed that the
secretion of galectin-3 by tumors represents a novel pathway to
escape NKp30-mediated NK cell immunosurveillance (85).
NCR-MEDIATED CONTROL OF
TUMORICIDAL PATHWAYS
The NCRs have been proposed to bind to many cellular ligands
which are implicated in NK cell surveillance of tumor cells. Many
of these interactions have been shown to evoke the cytotoxic
and cytokine-secreting functions of NK cells. However, it is
also possible that the NCRs may regulate other anti-tumor
pathways. For melanoma metastases, NK cells were attributed
to play a major role (99). However, ILC1 are phenotypically
closely related to conventional NK cells as both these cell-
types express T-bet and secrete IFN-γ (132, 133). ILC1 are
characterized by higher TRAIL expression than NK cells due
to tissue-imprinting by TGF-β (134). TRAIL (TNFSF10) can
bind to TRAIL receptors (TRAIL-Rs), such as TRAIL-R1 in
humans and TRAIL-R2 in humans and mice, which carry
death domains that can induce caspase-8-mediated apoptosis of
TRAIL-R+ tumor cells. TRAIL expression can be induced on NK
cells activated by various cytokines and interferons (135–137)
and several reports have described NK cell-mediated clearance
of TRAIL-sensitive transplantable tumors (135, 138), chemical-
induced fibrosarcoma (139), liver metastases (135, 139, 140), and
hematological malignancies (141).
NKp46 was shown to regulate TRAIL surface expression
resulting in the diminished cytotoxicity of TRAIL-R+ target cells
by NKp46-deficient NK cells and ILC1 (142, 143). The NKp46-
mediated pathway that regulates surface TRAIL expression
remains to be fully characterized but appears to involve a post-
transcriptional mechanism (142, 143). Whether NKp46 can
regulate surface TRAIL expression when expressed by other
immune cell subsets, such as γδ T cells and CD8+ T cells that
have been expanded with IL-15, remains to be determined. These
data show that NKp46 can endow NK cells or ILC1 with the
ability to lyse TRAIL-sensitive tumors as well as contribute to
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Gene location NCR ligand disease association Reference
(PubMed ID)




7q22.3 Intelligence (MTAG) 29326435
Educational attainment (MTAG) 30038396
Educational attainment (years of
education)
30038396
Cognitive performance (MTAG) 30038396
PCNA 20p12.3 No data available
VMAC (vimentin) 19p13.3 Post bronchodilator FEV1/FVC ratio 26634245
CFP Xp11.23 No data available
NCR2 6p21.1 Alzheimer’s disease biomarkers
(p-tau measurement)
23562540 PDGFD 11q22.3 Interferon gamma levels 27989323
Corticosteroid-induced adrenal
suppression (peak cortisol < 350 nmol/L)
29551627
Total ventricular volume (brain
measurement)
21116278 Corticosteroid-induced adrenal
suppression (peak cortisol < 500 nmol/L)
29551627
LDL cholesterol 21347282
Telomere length 29151059 Blood protein levels 29875488
30072576





20q13.12 Bacterial meningitis 28928442
Psoriasis 20953189
Velopharyngeal dysfunction 29855589
Lung function (FEV1/FVC) 30595370
NID1 1q42.3 Urate levels in overweight individuals 25811787
Cutaneous nevi 21478494





NCR3 6p21.33 C3 and C4 complement levels 23028341 BAG6 6p21.33 Small cell lung carcinoma 28604730
Diastolic blood pressure 28739976
21909115
Susceptibility to shingles 28928442 Systolic blood pressure 28739976
27618447
Blood protein levels 29875488 Feeling worry 29500382







28240269 Urinary tract infection frequency 28928442




14q22.3 Blood protein levels 30072576
Protein biomarker 23056639
No data available
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Highest math class taken (MTAG) 30038396
Heel bone mineral density 30598549
TRAIL-mediated immunoregulation of infectious diseases, tissue
inflammation (144–146), and potentially autoimmunity. It will
also be interesting to see which NKp46 ligands can induce surface
TRAIL expression in NK cells and ILC1 and the functional
consequence for TRAIL-sensitive tumors in vivo.
Control of Malignancy by Unconventional
NCR+ Lymphocyte Subsets
Until recently NCR expression was considered to be restricted to
NK cells. The NCRs have now been shown to be expressed by
CD8+ T cell populations and γδ T cells expanded with IL-15,
in addition to ILC1 and subsets of ILC3. Moreover, antibody-
mediated stimulation of NKp44 and NKp46 on “NK-like” IL-15-
expanded IEL CTL elicits the secretion of IFN-γ showing that
these NCRs can function independently of TCR stimulation in
T lymphocytes (31). Moreover, a population of NKp30+ CD8+ T
cells with anti-tumor potential was shown to be induced by IL-
15 (94). These NKp30+ CD8+ T cells exhibited high “NK-like”
anti-tumor activity and NKp30 synergized with TCR signaling to
control tumor growth in a preclinical xenograft mouse model.
Murine γδ T cells do not express NKp46, however, all
three NCRs are expressed on human γδ T cells following
continuous stimulation with TCR agonists or mitogens in the
presence of IL-2 or IL-15 (30). Interestingly, NCR induction
was mostly restricted to the Vδ1+ T cell subset and not Vδ2+
T cells. Like NK cells, the NCR+ Vδ1+ T cells were highly
cytolytic against primary leukemia cells and tumor cell-lines in
redirected cytotoxicity assays and NCR triggering also enhanced
the expression of IFN-γ. Based on these observations, IL-15
expanded populations of “NK-like” CD8+ or Vδ1+ T cells that
express NCRs have tremendous potential to be used clinically
for adoptive cancer immunotherapy (147). The acquisition of
NCRs by Vδ1+ T cells and CD8+ T cells is thought to require
strong TCR activation, which is consistent with the oligoclonal
expansion of gut IEL CTL in celiac disease that express a highly
restricted TCR repertoire (31).
Although unconventional NCR+ lymphocyte subsets have
been implicated in tumor surveillance they may also promote
immunosuppression and facilitate tumor immune evasion.
For example, a unique CD3−CD56+ ILC population was
recently described that inhibits tumor-infiltrating lymphocytes
(TILs) from high-grade serous ovarian carcinomas (148). The
CD3−CD56+ ILC population was associated with a reduced
TIL expansion and altered TIL cytokine production. This
novel population of CD3−CD56+ ILCs exhibited low cytotoxic
potential, secreted IL-22, and exhibited a transcriptional profile
overlapping that of NK cells and other ILCs. NKp46 was highly
expressed by the regulatory CD3−CD56+ ILC population and
NKp46 signaling promoted the ability to suppress TIL expansion
in co-culture (148).
Group 2 ILCs (ILC2s) secrete large amounts of type 2
cytokines, such as IL-5, IL-9, and IL-13, which promote
alternative macrophage activation, eosinophilia, and goblet cell
hyperplasia to limit parasite infection (149, 150). Increased levels
of hyperactivated ILC2s expressing NKp30 and Chemoattractant
receptor-homologous molecule expressed on Th2 cells (CRTH2)
are found in patients with peripheral acute promyelocytic
leukemia (APL). APL blasts were found to express high levels of
surface B7-H6 and prostaglandin D2 (PGD2) that bind to NKp30
and CRTH2 (151) on ILC2s, respectively, to drive potent IL-13
secretion and activation of IL-13R+ myeloid-derived suppressor
cells (152). Disruption of this tumor immunosuppressive axis by
specifically blocking PGD2, IL-13, and NKp30 signaling partially
normalized ILC2 andMDSC levels resulting in enhanced survival
in leukemic mice (152).
NCRs AND THEIR LIGANDS IN
INFECTIOUS DISEASE
The central role of the NCRs in resistance to infectious
disease is exemplified by the susceptibility of NKp46-deficient
mice to infection with different microorganisms. For example,
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human metapneumovirus (HMPV) causes acute respiratory
tract infections in infants and children worldwide that can
be fatal in immunosuppressed hosts. HMPV-infected cells
express an unidentified ligand for NKp46 and NKp46-deficient
mice are more susceptible to HMPV infection (153). The
NCRs have also been shown to contribute to humoral
immune responses and the generation of protective pathogen-
specific antibodies. For example, deficiency in NKp46 resulted
in the impaired maturation, function, and migration of
NK cells to regional lymph nodes of mice infected with
murine cytomegalovirus (MCMV). This was accompanied by
a reduction in CD4+ T cell activation and follicular helper
T cell generation leading to diminished B cell maturation
in germinal centers and reduced titers of MCMV-specific
antibodies (154).
Given the central role of NCRs in resistance to infectious
disease, it is unsurprising that pathogens have evolved
mechanisms to avoid NCR recognition. Herpesviruses are
DNA viruses that have evolved various strategies of immune
evasion as exemplified by their ability to establish latent infection
with limited transcription of viral genes. Cells infected with
human cytomegalovirus (HCMV) and human herpesvirus 6B
(HHV6B) can express the NKp30 ligand, B7-H6. Both HMCV
and HHV6B have evolved strategies to downregulate B7-H6 and
ligands for other activating NK cell receptors, such as NKG2D,
from the cell-surface, thus impairing NK cell recognition of
virus-infected cells (155, 156). In the case of HCMV infection,
HCMV expressed two gene products US18 and US20, that
interfere with B7-H6 surface expression by promoting the
lysosomal degradation of B7-H6 (155).
Many of the genes for the NCRs and their ligands are
associated with infectious diseases highlighting the importance of
theNCRs for pathogen recognition (Table 2). For example,NCR2
is associated with chronic periodontitis in pregnant women and
NCR3 is associated with susceptibility to cold sores and shingles
(Table 2). Here we document various NCR ligands that have been
reported to play a role in pathogen surveillance by NK cells and
other NCR+ immune cell subsets (Figure 2).
Hemagglutinins and
Hemagglutinin Neuraminidases
Even though the NCRs were first identified based on the
ability to lyse certain tumor cell-lines, some of the first NCR
ligands identified were viral proteins. Hemagglutinins (HA) from
influenza (53, 66) and hemagglutinin-neuraminidases (HN) from
parainfluenza, Sendai, and Newcastle disease viruses (53, 55)
expressed on infected cells were shown to bind to NKp46 and
NKp44. HAs from poxviruses, such as vaccinia and ectromelia,
were also identified as ligands for NKp30 and NKp46 (54).
However, the NCRs do not bind to HA from measles virus,
showing that whilst the NCRs are capable of recognizing a broad
range of viral HA and HNs there is some selectivity, which
is predominantly dependent on α-2,3- and α-2,6-sialylated O-
glycans on NCRs (53, 55, 56).
The interaction of viral-encoded HA and HNs on the surface
of infected cells results in NK cell activation via NKp46 and
NKp44 (53, 55, 56) and binding of the HN of Newcastle
disease virus to NKp46 results in activation of downstream
signaling molecules in the ITAM pathway e.g., Syk and surface
upregulation of TRAIL on murine NK cells (157). In support
of these observations, mice deficient in NKp46 expression are
more susceptible to infection with influenza A virus (158, 159).
In contrast, the interaction of NKp30 with HA expressed on
the cell-surface or shed from vaccinia-infected cells counteracted
activation by NKp46 resulting in the inhibition of NK cell lysis
(54), suggesting a novel pathway of viral immune escape via
NKp30. Moreover, exposure of NK cells to influenza virions or
soluble HA can result in lysosomal degradation of the CD3ζ
signaling chain and a reduction of NK cell cytotoxicity mediated
by NKp46 and NKp30 (160). In contrast, the cleavage of sialic
acid residues from NKp46 by the influenza virus neuraminidase
(NA) was proposed as a mechanism of immune evasion by
disrupting NKp46-binding to the viral HA and inhibitors specific
for the influenza NA enhanced NKp46 recognition and virus
clearance (161).
Human parainfluenza virus type 3 (HPIV3) is a virus that
causes various respiratory illnesses, such as pneumonia, croup,
and bronchiolitis, during infancy and childhood. Even though
reinfection with HPIV3 throughout life is common there is
no development of immunological memory and currently no
effective vaccine or anti-viral therapies available. Poor T cell
proliferation is observed following HPIV3 infection, which may
be responsible for the lack of memory associated with the virus.
NK cells have been shown to induce T cell cycle arrest in a
contact-dependent manner, which was shown to be dependent
on NKp44 and NKp46 but not NKp30 recognition of the HPIV3
HN on HPIV3-infected monocytes co-cultured with allogeneic-
mixed lymphocytes (57). Consequently, the authors proposed
that the success of future vaccines to HPIV3 may require the
generation of modified HN proteins that retain immunogenicity
but do not interact with NKp44 or NKp46.
Human Cytomegalovirus Tegument
Protein pp65
Intracellular staining of human cytomegalovirus (HCMV)
infected fibroblasts revealed an unidentified protein that
interacted with NKp30-Fc fusion protein. Purified virions
from HCMV-infected fibroblasts also bound to NKp30-Fc but
not to control Fc-fusion proteins. These data suggested the
unidentified viral protein that interacted with NKp30 may
be incorporated into HCMV virus particles. The NKp30 Fc
fusion was used to immunoprecipitate proteins from HCMV-
infected fibroblasts and the HCMV-encoded tegument protein
pp65 was subsequently identified as a ligand for NKp30 using
mass spectrometry (79). HCMV pp65 was shown to bind
directly to NKp30 and induce the dissociation of the signaling
adaptor CD3ζ. HCMV-infected fibroblasts were found to be
less susceptible to NK cell cytotoxicity compared to fibroblasts
infected with a pp65-deficient HCMV or in the presence of
blocking antibodies to NKp30. Thus, pp65 furnishes HCMVwith
a novel immune escape pathway by disrupting the surveillance of
virus-infected cells by NKp30.
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Flavivirus Proteins
NKp44 Fc-fusion proteins have also been shown to interact with
purified envelope protein from the flaviviruses, dengue virus
(DV), andWest Nile Virus (WNV) andWNV virus-like particles.
NKp44 was shown to specifically bind to domain III of the
envelope protein from WNV, which also bound to NK cells
expressing high levels of NKp44 and the binding of infectious
WNV and WNV-infected cells stimulated NK cell degranulation
and IFN-γ secretion in an NKp44-dependent manner (74).
Unlike the interaction with viral hemagglutinins, NKp44 binding
to domain III of the DV and WNV envelope proteins was
independent of glycan-linked sialic acid residues on NKp44.
Bacterial NCR Ligands
In contrast to viral ligands, the NCRs have also been shown
to bind directly to molecules encoded by bacteria and parasites
in addition to host molecules exposed on the surface of cells
infected with bacteria. For example, an Fc-fusion protein of
NKp44 (NKp44-Fc), but not NKp30 or NKp46, was shown
to bind to Mycobacterium bovis (M. bovis), M. tuberculosis,
Nocardia farcinica, and Pseudomonas aeruginosa (75, 76). NKp44
was specifically shown to bind to cell wall components, such
as arabinogalactan-peptidoglycan (mAGP) as well as to mycolic
acids and arabinogalactan and derivatives, from M. tuberculosis.
Whilst a direct role in NK cell cytotoxicity could not be
demonstrated, anti-NKp44 antibodies inhibited mAGP and
BCG-induced CD69 expression on IL-2-activated NK cells,
suggesting NKp44 recognition of bacterial wall components may
sustain NK cell activation during infection with M. tuberculosis
(76). In contrast to NKp44, NKp46 was reported to play a
dominant role in the lysis of mononuclear phagocytes infected
with M. tuberculosis (59). NKp46 was subsequently shown to
recognize vimentin expressed on the surface of cells infected
with M. tuberculosis (60). Antibodies to vimentin inhibited NK
cell lysis of monocytes infected with M. tuberculosis, whereas
transfection of vimentin enhanced NK cell lysis of Chinese
hamster ovary cells (60).
Fusobacterium nucleatum and Porphyromonus gingivalis are
involved in the pathogenesis of periodontitis. The severity
of periodontal disease is determined by the host’s immune
response. Alveolar bone loss occurred in wild-type mice but was
minimal in NKp46-deficient mice in an oral infection model
using Fusobacterium nucleatum or Porphyromonus gingivalis
(61). Expression of an NKp46 ligand by F. nucleatum was
demonstrated by the binding of a NKp46-Fc and the activation
of NKp46 reporter cells as well as the secretion of TNF-α from
wild-type but not NKp46-deficient NK cells (61). Interestingly,
NCR2, but not NCR1, is associated with chronic periodontitis in
humans (Table 2) (162), which could reflect cross-talk in NCR
signaling (163).
Parasite NCR Ligands
Parasite infection has also been shown to induce the expression
of NCR ligands. Fc fusion proteins of NKp30 and NKp46 were
shown to specifically bind to the Duffy binding-like (DBL)-
1 α domain of Plasmodium falciparum erythrocyte membrane
protein-1 (PfEMP-1), which is expressed on the cell-surface of
parasitized erythrocytes (58). NK cells lysed erythrocytes infected
with P. falciparum, which was blocked by antibodies to NKp30
and NKp46 with the greatest inhibition observed when both
antibodies were used in combination.
Fungal NCR Ligands
NKp46 and NKp30 have been shown to interact with fungal
ligands. Both mouse and human NKp46 were shown to bind to
the emerging fungal pathogen, Candida glabrata but not to C.
albicans, C. parapsilosis, C. krusei, or Cryptococcus gattii (63). Fc
fusion proteins from human and mouse NKp46 were specifically
shown to bind to the C. glabrata adhesins Epa1, Epa6, and Epa7.
The Epa proteins are lectins that bind to glycans to facilitate theC.
glabrata infection of mammalian cells and mutation of O-linked
glycosylation of Threonine 225 of mouse and human NKp46
abolished binding to C. glabrata Epa proteins (63). Moreover,
the clearance of systemic C. glabrata infection was impaired in
NKp46-deficient mice.
NKp30 mediates the recognition of Cryptococcus neoformans
and C. albicans resulting in the formation NK cell-fungal
conjugates and direct fungal killing (164). NKp30 was specifically
shown to bind to the fungal cell wall component β-1,3 glucan to
stimulate the polarization of cytotoxic granules in NK cell-fungal
conjugates, which enhanced the release of perforin required for
fungal cytotoxicity (86). Rather than blocking the interaction
betweenNK cells and fungi, soluble β-1,3 glucan enhanced fungal
killing (86). Fungal infections are the leading cause of death
in AIDS patients and NK cells from HIV-infected patients had
reduced expression of NKp30. IL-12 and β-1,3 glucan restored
NK cell expression of NKp30 and fungal killing by NK cells (86,
164). The activation of src family kinases by NKp30 synergized
with β1 integrin signaling and the activation of integrin-linked
kinase (ILK) and Rac1, which converged into a central PI3 kinase
signaling pathway that was required for fungal killing by NK
cells (87).
Complement Factor P (properdin)
The complement system is an evolutionary ancient component
of the innate immune response. Complement factor P (CFP,
also known as properdin) is a plasma glycoprotein that binds to
microbial surfaces and is the only known positive regulator of
the alternative pathway of complement (165). CFP stabilizes the
C3- and C5-convertase enzyme complexes that ultimately leads
to the formation of the membrane attack complex and target cell
lysis. NKp46 was shown to bind to CFP. Patients deficient in CFP
are more susceptible to lethal Neisseria meningitidis due to an
inability to activate the alternative pathway of complement (166).
CFP was shown to bind to a recombinant NKp46 Fc-fusion
protein and to activate NKp46 reporter cells but could not induce
classical NK cell activation characterized by degranulation and
IFN-γ secretion (64). Instead CFP induced the upregulation
of genes encoding the leucine zipper protein FosB and the
chemokine XCL1 (also known as lymphotactin). Thus, CFP
binding to NKp46 was proposed to activate a non-canonical
pathway of gene expression in NK cells. In agreement with
patients deficient in CFP, NKp46 and ILC1were required formice
to survive infection withN. meningitidis. Moreover, the beneficial
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effects of CFP supplementation forN. meningitidis infection were
dependent on NKp46 and ILC1 (64).
Unconventional Roles for NCRs in the
Control of Infection
NKp30 is also expressed on γδ T cells (30) bearing TCR Vδ1
but not TCR Vδ2. Circulating γδ T cells are normally devoid of
NCR expression. However, all three NCRs were induced on γδ T
cells following TCR engagement in conjunction with cytokines,
such as IL-2 and IL-15 (30). Moreover, mAb cross-linking of
NKp30 on NCR+ Vδ1 T cells, and to a lesser extend NKp44
and NKp46, induced the chemokines CCL1, CCL2 and CCL3,
which suppressed HIV infection by binding the HIV co-receptor,
CCR5 (167).
NCRs AND THEIR LIGANDS
IN DEVELOPMENT
In steady state, human uterine NK (uNK) cells maintain
endometrial arteries (168). However, during pregnancy, uterine
NK cells maintain key developmental processes, such as
trophoblast invasion, remodeling uterine vasculature, and the
promotion of fetal growth (169). The tissue origins of uNK
remain obscure and are thought to constitute a heterogenous
population derived from local endometrial NK cells as well as
conventional NK cells recruited from the circulation (169, 170).
Uterine NK cells possess limited cytotoxicity and actively secrete
cytokines, chemokines, GFs, and angiogenic factors required for
the correct remodeling of maternal spiral arteries and likely
function by promoting the recruitment of invading trophoblast
cells and promoting angiogenesis during pregnancy (171).
The NCRs have been reported to be expressed by uNK
(171–173) and the ligands for NKp30 and NKp44 are also
expressed by trophoblast cells (171). Consequently, trophoblast
cells have the potential to directly stimulate uNK functions via
the NCRs and ligation of the NCRs with specific antibodies
resulted in the secretion of cytokines, chemokines, GFs, and
angiogenic factors by uNK (171–173). Thus, NCR expression
endows uNK with the capacity to orchestrate key developmental
processes at the fetal-maternal interface following interactions
with trophoblast cells or other NCR ligands expressed in decidua.
Uterine NK and peripheral blood NK (pNK) operate in different
tissue microenvironments and also differ in NCR expression.
For example, resting pNK do not express NKp44 unlike uNK.
The decidual stroma expresses the cytokines IL-15, IL-18, and
TGF-β, that are required for successful pregnancy. Uterine NK
were found to express distinct NKp30 and NKp44 splice variants
compared to pNK, characterized by predominant expression
of the inhibitory NKp30c and NKp44-1 isoforms and lower
amounts of the activating NKp30a/b and NKp44-2/3 isoforms
(174). A combination of IL-15, IL-18, and TGF-β shifted the
pNK NCR splice variant expression profile toward that of uNK
suggesting the decidual tissue microenvironment can confer a
decidual-like uNK phenotype on pNK (174).
NCRs AND THEIR LIGANDS IN ALLERGY
Allergic disease is caused by inappropriate immune responses
to harmless antigens driven by type 2 cytokines. Very few
papers have documented a role for NK cells or the NCRs in
allergic disease. However, recent studies have suggested that NK
cells and the NCRs may be important in allergy due to the
immunoregulatory activity of NK cells on other immune cell
subsets (175) and NK cells have also been shown to drive allergic
responses independently of T and B cells (176, 177). NKp46-
deficient mice were shown to have reduced skin and airway
hypersensitivity (178). In a delayed type IV hypersensitivity
model of airway inflammation, the number of IFN-γ producing
NK cells and the proliferation of OVA-specific T cells was reduced
following intranasal OVA challenge in NKp46-deficient mice,
suggesting that differences in the stimulation of T cells resulting
in an altered cytokine profile upon challenge with ovalbumin
(OVA) (178). These results suggested that NKp46 signaling
enhances allergic responses. In contrast, a separate study using
a delayed type I hypersensitivity model, showed that NKp46
signaling suppressed the development of airway eosinophilia
following intranasal OVA challenge (179). It will be interesting
to see which NKp46-expressing cell types, such as NK cells, ILC1
or ILC3, might be responsible for either suppressing (179) or
augmenting (178) airway inflammation in models of type I and
type IV hypersensitivity, respectively.
NCR expression by other lymphocyte subsets may also
regulate allergic response. For example, whilst ILC2s secrete type
2 cytokines to limit parasite infection they are also important
contributors to allergic inflammation (149, 150). Activated
human ILC2s can express NKp30 and stimulation of ILC2s with
B7-H6 induced the rapid production of type 2 cytokines, such
as IL-13, which was blocked by anti-NKp30 blocking mAb and
galectin-3 (180). Higher expression of B7-H6 is observed in
skin lesion biopsies from patients with atopic dermatitis and
stimulation of keratinocytes with proinflammatory as well as type
2 cytokines upregulated B7-H6 expression leading to enhanced
ILC2 production of type 2 cytokines. Thus, the NKp30-B7-H6
interaction is a novel cell contact-dependent interaction that
can mediate ILC2 activation and is a potential target for the
development of novel therapeutics for atopic dermatitis and
possibly other atopic diseases (180).
NCRs AND THEIR LIGANDS
IN AUTOIMMUNITY
NK cell have also been implicated in the development of
autoimmune diseases, such as type 1 diabetes (181–184). NKp46-
deficient mice were reported to be resistant to the development
diabetes induced by streptozotocin and a soluble NKp46-Fc
protein blocked the development of diabetes in mice (62).
NKp46 was suggested to play a dominant role in NK cell
cytotoxicity of human pancreatic β-cells through the recognition
of an as yet unidentified NKp46 ligand expressed in the β-cell
insulin granules (97). Anti-NKp46 mAbs that can induce the
downregulation and lysosomal degradation of mouse and human
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NKp46 have now been developed, which may be effective in the
treatment of diabetes (185, 186).
Primary Sjogren’s syndrome (pSS) is a chronic autoimmune
disease characterized by lymphocytic exocrinopathy that can
affect up to 0.1 to 0.6% of the general population. An excess
accumulation of NK cells in minor salivary glands of pSS patients
is correlated with the severity of exocrinopathy. B7-H6, the
ligand for NKp30, is expressed in minor salivary glands and a
higher cell-surface expression of NKp30 on circulating NK cells
is observed in pSS patients compared to healthy controls (187).
A case control study of genetic polymorphisms revealed that
a single nucleotide polymorphism (SNP) rs11575837 (G > A)
in the promoter region of NCR3 was associated with reduced
transcription and protection from pSS. These findings suggested
that NK cells may promote NKp30-dependent inflammation in
salivary glands and blockade of the NKp30-B7-H6 interaction
may represent a novel clinical target for pSS (187).
NCR-BASED CANCER
IMMUNOTHERAPIES
In addition to the development of therapeutic antibodies to the
NCRs for potential use in the treatment of autoimmune diseases,
such as diabetes (see above), several reports are now beginning
to provide evidence that the NCRs and their ligands can be
successfully targeted for cancer immunotherapy. Moreover, these
systems have shown to be effective in various pre-clinical mouse
tumor models highlighting the tremendous potential of NCR-
based strategies for tumor immunotherapy.
Virotherapy
Reovirus is a double-stranded RNA virus that infects much of
the population during childhood causing mild or subclinical
infections. Interestingly, reovirus efficiently infects tumor cells
and is currently be tested in human clinical trials as a potential
cancer virotherapy although the mechanism whereby reovirus
infected tumor cells are recognized and eliminated by the
immune system is not well-understood. The reovirus σ1 protein
forms an elongate trimer that serves as a viral attachment protein
(188). Human and mouse NKp46 were shown to bind to reovirus
σ1 protein in a sialic acid-dependent manner that led to NK cell
activation in vitro (189) (Figure 2). NK cells and NKp46 were
shown to be essential for the clearance of reovirus infection from
the lungs of infected mice and for the success of reovirus-based
tumor therapy (189).
Bi-Specific T Cell Engagers (BiTE)
The NKp30/B7-H6 interaction has been targeted using various
therapeutic strategies. One approach has been to target T cells
to B7-H6 expressing tumors using a BiTE that incorporated a
single-chain FV (ScFV) to B7-H6 fused to an anti-CD3ε ScFV.
The B7-H6-specific BiTE promoted T cell cytotoxicity and IFN-
γ secretion against B7-H6+ tumor cells, which enhanced the
survival of lymphoma-bearing mice and decreased the tumor
burden of melanoma- and ovarian cancer-bearing mice (190).
Similar conceptual approaches, have involved fusing the B7-H6
ectodomain (with the aim of engaging NKp30 on NK cells) to
either an anti-Human Epidermal Growth factor 2 (HER2) scFv to
enhance NK cell killing of HER2+ breast cancers (191) or an anti-
CD20 scFv to target lymphomas (192, 193). Such reagents were
reported to be effective at nM concentrations and to enhance
ADCC mediated by therapeutic antibodies, such as trastuzumab,
cetuximab, and rituximab (191–193).
NCR-Based Chimeric Antigen
Receptors (CARs)
Yet another therapeutic strategy has been to engineer chimeric
antigen receptor (CAR) constructs that incorporate either the
NKp30 ectodomain (NKp30-CAR) or an anti-B7-H6 scFv
(B7H6-specific CAR) with TM domains fused to the CD3ζ or
and/or CD28 cytoplasmic signaling domains for cell-surface
expression in T or NK cells intended for use in adoptive
cancer immunotherapy (194–196). NKp30-CAR and B7-H6-
specific CAR T cells elicited robust cellular cytotoxicity and IFN-
γ secretion when co-cultured with B7-H6+ tumor cells. Dendritic
cells (DCs) also enhanced IFN-γ secretion from NKp30-CAR
expressing T cells, whereas B7-H6-specific CAR T cells exhibited
little self-reactivity to DCs and monocytes expressing B7-H6
ligands. The adoptive transfer of T cells expressing NKp30-CAR
or B7-H6-specific CAR T cells enhanced the survival of mice
bearing RMA lymphoma cells transduced with B7-H6.Moreover,
mice that remained tumor-free, were resistant to subsequent
rechallenge with B7-H6-deficient parental RMA tumor cells
(194, 195). NKp44- and NKp46-derived CARs have also been
developed and were shown to elicit clinical efficacy for various
solid tumors that express ligands for these receptors (197, 198).
DISCUSSION
The NCRs were originally identified as activating receptors
expressed on NK cells. However, it is now apparent the NCRs
are expressed by ILCs in addition to adaptive Vδ1+ and CD8+
T cells. The NCRs have been shown to synergize with TCR
signaling as well as function independently on T cells. Thus,
like NK cells, Vδ1+ and CD8+ T cells expressing NCRs hold
potential for adoptive cancer immunotherapy (147, 199). It will
be interesting to see how NCR+ Vδ1 T cells and CD8+ T cell
functions are regulated by the range of NCR ligands now reported
in the literature.
The NCRs can interact with soluble as well as membrane
bound ligands. Such polyfunctionality is not uncommon
in the immune system (25). For example, the activating
immunoreceptor OSCAR signals via FcRγ and possesses two Ig-
like domains similar to NKp46 and genes for both proteins are
encoded in the Leukocyte Receptor Complex (LRC), suggesting
a common evolutionary origin (200). OSCAR interacts with
at least three different types of ECM collagens to costimulate
osteoclastogenesis (201–203) and also binds to the secreted
collagen-like lectin, Surfactant Protein D (SP-D) (204). The LRC-
encoded immunoreceptors, LAIR-1 and LAIR-2, also bind to
multiple ECM collagens as well as SP-D (205–207). Moreover,
NKG2D, a member of the C-type lectin family of activating NK
cell receptors, is highly promiscuous and binds to a number of
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cell-surface and shedMHC class I-like ligands to regulate NK cell
functions (199, 208–211). However, in contrast to OSCAR, LAIR-
1 and−2, and NKG2D, which all bind structurally similar surface
or soluble ligands, respectively, the NCRs have been reported
to bind a structurally diverse set of ligands. Thus, many open
questions regarding NCR ligand binding still remain, such as
how can a given NCR bind to such a broad range of structurally
diverse ligands? Conversely, how can the structurally diverse
NCRs all bind the same classes of ligands, such as viral HAs
and cellular HS GAGs? Structural studies are clearly required
to resolve many of these outstanding questions and may reveal
fascinating insights into the polyfunctionality of the NCRs as well
as intriguing comparisons for other immunoreceptor families.
Such a structurally diverse set of soluble and surface bound
NCR ligands might also be expected to induce different strengths
and duration of activating or inhibitory NCR signaling that may
regulate NK cell activity in different tissues and inflammatory
settings. Recent data have raised the importance of secreted
ligands in the “alternative activation” of NK cells and the NCRs
are no exception (64, 67, 210). For example, PDGF-DD has been
reported to bind to NKp44 to induce the secretion of IFN-γ
and TNF-α and chemokines, such as CCL1, CCL3, CCL4, XCL1
and XCL2 (67), whereas CFP binding to NKp46 only elicits the
expression of XCL1 (64). Firstly, these data challenge the view
that stimulation with soluble or shed ligands invariably leads to
the desensitization of activating receptor pathways and NK cell
inhibition. Secondly, the range of different response to soluble
ligands suggests the NCR interaction with each ligand may be
tailored to the tissue microenvironment for a specific function
or to avoid immunopathology. For example, CFP binding to
NKp46, is critical for resistance to N. meningitidis infection,
which causes septicaemia and meningitis (64). It is conceivable
that the reduced NK cell activation induced by the CFP/NKp46
interaction may be desirable in the meninges given the proximity
of the inflammatory response to the brain. Further research into
the molecular basis and cell biology of NCR signaling for surface-
bound and soluble ligands is warranted to fully understand
how soluble ligands, such as PDGF-DD and CFP, as well as
shed ligands, such as MULT1, (210), evoke appropriate NK cell
activation in different organs and tissues and within the tumor
microenvironment (212). Such approaches will inform methods
to enhance NK cell targeting and to stimulate or inhibit their
functions in vivo and will lead to the development of novel
clinical interventions (212, 213). For example, CARs have already
been engineered for soluble growth factors, such as TGF-β, that
function in T cells and promote anti-tumor responses in vivo
(67, 214, 215).
Many of the proposed NCR ligands are normally localized
to the nucleus or cytoplasmic proteins, such as BAT3, NKp44L,
and PCNA. However, the cellular pathways responsible for
the cell-surface localization of these ligands and their selective
upregulation in malignant vs. non-malignant cells still remain
to be characterized in molecular detail. These questions are
critical for understanding how the NCR ligands regulate the
activity of NK cells and other NCR+ immune cell subsets in
different tissues and pathological processes. Interestingly, the
NCRs and their ligands are associated with a diverse range of
diseases and biological traits (Table 2). It might be expected
that many of these disease associations are independent of
the NCRs and result from changes to the primary biological
function of the NCR ligand in question. However, it is
also feasible that the NCRs and their ligands could play a
pathogenetic role for some of these aforementioned diseases.
Further research into the role of the NCRs and their ligands
that are genetically associated with disease should be encouraged
and will provide novel insights into the role of tissue NK
cells for diseases that may have an as yet unrecognized
immunopathological component.
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